Predictive value of serum cytokine level in the assessment of complications after liver transplantation
https://doi.org/10.23873/2074-0506-2021-13-1-33-40
Abstract
Introduction. One of the urgent tasks in modern transplantology is the search of biomarkers for predicting and early diagnosis of graft dysfunction.
Objective. The study objective was to determine the biomarkers of liver graft dysfunction.
Material and methods. We have examined 19 recipients who underwent liver transplantation and 36 healthy blood donors. Levels of 7 serum cytokines were measured by multiparametric fluorescence analysis with magnetic microspheres (xMAP technology, Luminex 200, USA). Statistical analysis was carried out by methods of nonparametric statistics. To determine the predictive value of the test, a ROC-analysis was performed.
Results and discussion. We found that the interleukin-8 level was 3.6 times higher in recipients with liver graft dysfunction compared to those who had an uneventful postoperative course. The diagnostic sensitivity of the test was 75%, the specificity was 91%, and negative predictive value was 84.6.
Conclusion. Serum interleukin-8 measurement provides a biomarker for early predicting a post-transplant liver graft dysfunction development
About the Authors
A. Yu. Maksimova
Ural State Medical University
Russian Federation
Russian Federation
Arina Yu. Maksimova, Junior Researcher of Central Research Laboratory, Department of General Pathology
3 Repin St., Ekaterinburg 620028
E. N. Bessonova
Sverdlovsk Regional Clinical Hospital № 1
Russian Federation
Russian Federation
Elena N. Bessonova, Dr. Sci. (Med.), Head of Gastroenterology Department
185 Volgogradskaya St., Ekaterinburg 620102
V. V. Bazarnyy
Ural State Medical University
Russian Federation
Russian Federation
Vladimir V. Bazarnyy, Dr. Sci. (Med.), Professor of the Department of Clinical Laboratory Diagnostics and Bacteriology
3 Repin St., Ekaterinburg 620028
References
1. Pereira CS, Carvalho AT, Bosco AD, Forgiarini Júnior LA. The Perme scale score as a predictor of functional status and complications after discharge from the intensive care unit in patients undergoing liver transplantation. Escala Perme como preditor de funcionalidade e complicações após a alta da unidade de terapia intensiva em pacientes submetidos a transplante hepático. Rev Bras Ter Intensiva. 2019;31(1):57–62.PMID: 30970092
2. Jadlowiec CC, Taner T. Liver transplantation: Current status and challenges. World J Gastroenterology. 2016;22(18):4438–4445. PMID: 27182155 https://doi.org/10.3748/wjg.v22.i18.4438
3. Zazula R, Prucha M, Tyll T, Kieslichova E. Induction of procalcitonin in liver transplant patients treated with anti-thymocyte globulin. Crit Care. 2007;11(6):R131. PMID: 18088403 https://doi.org/10.1186/cc6202
4. Хубутия М.Ш., Чжао А.В., Шадрин К.Б. Послеоперационные осложнения у реципиентов при трансплантации печени: современные представления о патогенезе и основных направлениях профилактики и лечения. Вестник Трансплантологии и искусственных органов. 2009;11(2):60–66. Khubutiya MSh, Zhao AV, Shadrin KB. Postoperative complications in liver transplant recipients: modern considerations of pathogenesis and main areas of prophylaxis and treatment. Russian Journal of Transplantology and Artificial Organs. 2009;11(2):60–66. (In Russ.).
5. Martínez JA, Pacheco S, Bachler JP, Jarufe N, Briceno E, Guerra J, et al. Accuracy of the BAR score in the prediction of survival after liver transplantation. Ann Hepatol. 2019;18(2):386–392. https://doi.org/10.1016/j.aohep.2019.01.002
6. Schlegel A, Linecker M, Kron P, Györi G, Oliveira ML, Müllhaupt B, et al. Risk assessment in high- and low-MELD liver transplantation. Am J Transplant. 2017;17(4):1050–1063. PMID: 27676319 https://doi.org/10.1111/ajt.14065
7. Perrakis A, Stirkat F, Croner RS, Vassos N, Raptis D, Yedibela S, et al. Prognostic and diagnostic value of procalcitonin in the post-transplant setting after liver transplantation. Arch Med Sci. 2016;12(2):372–379. PMID: 27186183 https://doi.org/10.5114/aoms.2016.59264
8. Hwang W, Lee J. Pathophysiologic implications of cytokines secretion during liver transplantation surgery. Int J Med Sci. 2018;15(14):1737–1745. PMID: 30588198 https://doi.org/10.7150/ijms.28382
9. Hassan L, Bueno P, Ferrón-Celma I, Ramia JM, Garrote D, Muffak K, et al. Early postoperative response of cytokines in liver transplant recipients. Transplant Proc. 2006;38(8):2488–2491. https://doi.org/10.1016/j.transproceed.2006.08.054
10. Klune JR, Bartels C, Luo J, Yokota S, Du Q, Geller DA. IL-23 mediates murine liver transplantation ischemia-reperfusion injury via IFN-γ/IRF-1 pathway. Am J Physiol Gastrointest Liver Physiol. 2018;315(6):991–1002. https://doi.org/10.1152/ajpgi.00231.2018
11. Woo YS, Lee KH, Lee KT, Lee JK, Kim JM, Kwon CHD, et al. Postoperative changes of liver enzymes can distinguish between biliary stricture and graft rejection after living donor liver transplantation: A longitudinal study. Medicine (Baltimore). 2017;96(40):е6892. https://doi.org/10.1097/MD.0000000000006892
12. Kim JM, Kim JH, Lee S-Y, Park JB, Kwon CHD, Kim SJ, et al. Prediction of biliary complications after livingdonor liver transplantation based on serum cytokine profile. Transplant Proc. 2014;46(3):861–864. https://doi.org/10.1016/j.transproceed.2013.11.038
13. Курабекова Р.М., Цирульникова О.М., Пашкова И.Е., Олефиренко Г.А., Гичкун О.Е., Макарова Л.В.и др. Диагностическая эффективность трансформирующего фактора роста бета 1 при оценке риска развития дисфункции трансплантата у детей-реципиентов печени. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(3):58–65. Kurabekova RM, Tsiroulnikova OM, Pashkova IE, Olefirenko AG, Gichkun OE, Makarova LV, et al. Diagnostic effectiveness of transforming growth factor beta 1 in assessing the risk of developing graft dysfunction in liver recipient children. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(3):58–65. (In Russ.). https://doi.org/10.22416/1382-4376-2019-29-3-58-65
14. Bolondi G, Mocchegiani F, Montalti R, Nicolini D, Vivarelli M, De Pietri L. Predictive factors of short term outcome after liver transplantation: A review. World J Gastroenterol. 2016;22(26):5936–49. PMID: 27468188 https://doi.org/10.3748/wjg.v22.i26.5936
15. Meier RH, Meyer J, Montanari E, Stéphanie L, Balaphas A, Muller Y, et al. Interleukin-1 receptor antagonist modulates liver inflammation and fibrosis in mice in a model-dependent manner. Int J Mol Sci. 2019;20(6):1295. https://doi.org/10.3390/ijms20061295
16. Joshi M, Oltean M, Patil PB, Hallberg D, Kleman M, Holgersson J, et al. Chemokine-mediated robustaugmentation of liver engraftment: a novel approach. Stem Cells Transl Med. 2015;4(1):21–30. PMID: 25473087 https://doi.org/10.5966/sctm.2014-0053
17. Chae MS, Kim JW, Chung HS, Park CS, Lee J, Choi JH, et al. The impact of serum cytokines in the development of early allograft dysfunction in living donor liver transplantation. Medicine (Baltimore). 2018;97(16):e0400. PMID: 29668595 https://doi.org/10.1097/MD.0000000000010400
18. Gras J, Wieërs G, Vaerman JL, Truong DQ, Sokal E, Otte JB, et al. Early immunological monitoring after pediatric liver transplantation: cytokine immune deviation and graft acceptance in 40 recipients. Liver Transpl. 2007;13(3):426–433. PMID: 17318867 https://doi.org/10.1002/lt.21084
19. Hull J, Ackerman H, Isles K, Hull J, Ackerman H, Pinder M, et al. Unusual haplotypic structure of IL-8, a susceptibility locus for a common respiratory virus. Am J Hum Genet. 2001;69(2):413– 419. https://doi.org/10.1086/321291
20. Zimmermann HW, Seidler S, Gassler N, Nattermann J, Luedde T, Trautwein C, et al. Interleukin-8 is activated in patients with chronic liver diseases and associated with hepatic macrophage accumulation in human liver fibrosis. PLoS One. 2011;6(6):e21381. PMID: 21731723 https://doi.org/10.1371/journal.pone.0021381
21. Sasaki T, Suzuki Y, Kakisaka K, Wang T, Ishida K, Suzuki A, et al. IL-8 induces transdifferentiation of mature hepatocytes toward the cholangiocyte phenotype. FEBS Open Bio. 2019;9(12):2105–2116. PMID: 31651102 https://doi.org/10.1002/2211-5463.12750
22. ClinicalTrials.gov Identifier: NCT03031470; ID Number: TPL-RPX- 01-Pilot study of reparixin for early allograft dysfunction prevention in liver transplantation. Аvailable at: https://clinicaltrials.gov/ct2/show/NCT03031470 [Accessed December 24, 2020]
Review
For citations:
Maksimova A.Yu., Bessonova E.N., Bazarnyy V.V. Predictive value of serum cytokine level in the assessment of complications after liver transplantation. Transplantologiya. The Russian Journal of Transplantation. 2021;13(1):33-39. https://doi.org/10.23873/2074-0506-2021-13-1-33-40
Views:
596
